Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Blood. 2020 Jun 4;135(23):2106-2109. doi: 10.1182/blood.2019004162.

Abstract

Publisher's Note: There is a Blood Commentary on this article in this issue.

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antigens, CD19 / therapeutic use*
  • Biological Products
  • Female
  • Follow-Up Studies
  • Humans
  • Immunotherapy, Adoptive
  • Lymphoma, Large B-Cell, Diffuse / immunology
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Lymphoma, Large B-Cell, Diffuse / therapy*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / immunology
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / therapy*
  • Prognosis
  • Survival Rate
  • Young Adult

Substances

  • Antigens, CD19
  • Biological Products
  • axicabtagene ciloleucel